# Title: Literature Review Summary on Integrated Genomic Analyses of Ovarian Carcinoma

Niguse Kelile Lema, Raqeebat Rafiu, Abdulqudus Oladega, Zaka Ullah 

## Introduction

High-Grade Serous Ovarian Carcinoma (HGS-OvCa) is the fifth leading cause of cancer-related deaths among women in the United States (*Sung et al, 2021*). This cancer type is characterized by high genetic complexity with poor survival rates. The standard treatment for HGS-OvCa Surgery followed by platinum-taxane chemotherapy. The main objective of this article is to understand the Genetic Landscape of High-Grade Serous Ovarian Cancer (HGS-OvCa).

## TP53 mutations
One of the key finding of this article is nearly all tumors (96%) exhibits TP53 Mutations, a tumors suppressor gene and play crucial role in regulating cell division and preventing cancer. Mutation in TP53 gene indicates uncontrolled cell growth and continues proliferation of cancerous cells. Additionally, low-frequency recurrent mutation were also observed in genes such as BRCA1, BRCA2, NF1, RB1, CDK12. The study also highlights the presence of copy number aberrations and DNA methylation changes.

The study found 113 important changes in DNA copy numbers, where certain cancer-promoting genes like CCNE1 and MYC were amplified, while tumor-suppressing genes were deleted. Additionally, 168 genes were silenced due to methylation, which further blocked the function of tumor suppressors, contributing to cancer growth.

## Subtypes of Ovarian Cancer
Based on gene expression profiles, four molecular subtypes identified. These molecular subtypes are Immunoreactive, Differentiated, Proliferative, and Mesenchymal. Each subtype has distinct gene expression profiles and clinical relevance.

## Impact on Survival
Tumors with BRCA1 or BRCA2 mutations have better survival outcomes compared to others. Researchers also discovered a set of 193 genes whose expression patterns can help predict how long a patient might survive, offering insights for improved treatment strategies.

## Pathway Insights and Therapeutic Targets
About 50% of tumors have defects in the homologous recombination (HR) pathway, making them treatable with PARP inhibitors. The NOTCH and FOXM1 signaling pathways also play a role in cancer growth. These findings suggest therapies targeting these pathways and specific genes could improve treatment for ovarian cancer patients.

## Conclusion
The study highlights the central role of TP53 mutations and significant heterogeneity in other aberrations less frequent recurrent mutations. Defect in the homologous recombination pathways make tumors more susceptible to treatment with PARP inhibitors. Additionally, the genomic landscape uncovered in this study provides valuable insights for therapeutic targeting and highlights the potential for personalized treatment strategies based on specific genetic and molecular alterations for HGS-OvCa.

## References
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4. PMID: 33538338.
Bell D, Berchuck A, Birrer M, Chien J, Cramer DW, Dao F, et al. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609â€“15. 

## Contributors
1.	Niguse Kelile Lema [Slack ID: U07KGNNU692] [email: nigusmov16@gmail.com]
2.	Raqeebat Rafiu [Slack ID: U07JH1CS4BV] [email: raraqeebat@gmail.com]
3.  Abdulqudus Oladega [Slack ID: U07JEADTFV3] [email: oladegakenny@gmail.com]
4.  Zaka Ullah [Slack ID: U07KH8KMKFB] [email: zakaullahx3@gmail.com]

## Useful Links 
1.	LinkedIn Video Post: https://www.linkedin.com/posts/niguse-kelile-lema_literature-review-on-integrated-genome-analysis-activity-7238881804122828800-NZIA?utm_source=share&utm_medium=member_desktop
2.	GitHub Markdown: https://lnkd.in/eKZ8zDC5

